The Alzheimer's Bottleneck Was Never the Drugs
The FDA just cleared the first blood test that can both confirm and rule out Alzheimer's pathology from a routine blood draw — in primary care, on analyzers already installed in 4,500 US labs. The $26,500-a-year drugs were never the constraint. The diagnosis was.
For three years, the story of the Alzheimer's drug market has been a puzzle. The science finally worked — two FDA-approved antibodies that measurably slow the disease, a $26,500-a-year price tag on one and $32,000 on the other, and more than seven million American patients. And yet the revenue never showed up. Eisai and Biogen's Leqembi, the market leader, booked roughly ¥29 billion — about $200 million — globally last quarter. Endpoints News described the trajectory politely as "disappointing." Lilly's Kisunla has trailed it.
This morning, the FDA cleared the thing that explains the gap.
Roche and Eli Lilly's Elecsys pTau217 blood test received FDA clearance on Monday — the first and only blood test cleared to both rule in and rule out amyloid pathology, the biological signature of Alzheimer's disease, using a single biomarker and one set of validated cutoffs, in primary care as well as specialty settings, for patients 55 and older with cognitive complaints. It runs on Roche's cobas analyzers — more than 4,500 of which are already installed in US clinical laboratories. No new hardware, no specialty referral, no spinal tap, no PET scanner.
To understand why that matters more than any drug approval this year, you have to understand what the diagnostic pathway looked like until today.
The funnel that strangled a franchise
The anti-amyloid drugs only work — and are only approved — for patients in the earliest symptomatic stages of Alzheimer's, with amyloid pathology confirmed by a test. That confirmation has required either a PET scan (thousands of dollars, machines concentrated in academic medical centers) or a lumbar puncture (invasive, unpopular, also specialist-gated). In front of both sits the scarcest resource in American medicine: the neurology appointment, with wait times routinely stretching many months.
The result is a funnel that leaks at every stage. An estimated 75% of people living with dementia worldwide are undiagnosed. Patients who do get referred often wait long enough that they progress past the early-stage window in which the drugs are approved — timed out of eligibility by the queue itself.
That is the market the drugmakers have been selling into: not seven million patients, but the thin trickle that survives the funnel. The drugs were never the constraint. The diagnosis was.
The FDA has cleared Alzheimer's blood tests before — Fujirebio's in May 2025, confined to specialty settings, and Roche's own pTau181 assay last October, a rule-out screen only. Monday's clearance is the first that closes the loop in both directions, in the doctor's office where cognitive complaints are actually first heard. A primary-care physician can now order amyloid confirmation the way they order a cholesterol panel.
Briefings like this land in members' inboxes before the market prices them in. Join free →
And the timing is not a coincidence the market can afford to ignore: Eisai and Biogen launch Leqembi's at-home subcutaneous starter dose this very week — meaning the diagnosis and the treatment just decentralized in the same month. The question is who captures the value as the funnel opens.
The rest of this briefing is for paid members: why Roche's installed-analyzer base makes this a razor-and-blade franchise, the reflexive math on Biogen at trough expectations, what Lilly actually bought by co-developing its competitor's diagnostic, where the bottleneck physically moves next (and the companies that own that chokepoint), and the bottom-line positioning framework.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.